FGFR1 and hepatocellular carcinoma: This highlights the clinical relevance of FGFR1 inhibition in overcoming resistance mechanisms and improving patient outcomes, particularly in advanced HCC where FGFR1 overexpression correlates with poor prognosis and treatment failure [133].